GB9925966D0 - Threapeutic vaccines against variable viruses and other targets - Google Patents

Threapeutic vaccines against variable viruses and other targets

Info

Publication number
GB9925966D0
GB9925966D0 GBGB9925966.5A GB9925966A GB9925966D0 GB 9925966 D0 GB9925966 D0 GB 9925966D0 GB 9925966 A GB9925966 A GB 9925966A GB 9925966 D0 GB9925966 D0 GB 9925966D0
Authority
GB
United Kingdom
Prior art keywords
component
targets
threapeutic
vaccines against
variable viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9925966.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GBGB9925966.5A priority Critical patent/GB9925966D0/en
Publication of GB9925966D0 publication Critical patent/GB9925966D0/en
Priority to EP00973003A priority patent/EP1226256B1/en
Priority to AT00973003T priority patent/ATE358727T1/de
Priority to HK03100373.4A priority patent/HK1048335B/en
Priority to PCT/GB2000/004191 priority patent/WO2001032893A1/en
Priority to JP2001535575A priority patent/JP4768944B2/ja
Priority to AU11560/01A priority patent/AU1156001A/en
Priority to ES00973003T priority patent/ES2284537T3/es
Priority to DE60034243T priority patent/DE60034243T2/de
Priority to CA002389339A priority patent/CA2389339A1/en
Priority to US11/124,971 priority patent/US7390881B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
GBGB9925966.5A 1999-11-02 1999-11-02 Threapeutic vaccines against variable viruses and other targets Ceased GB9925966D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB9925966.5A GB9925966D0 (en) 1999-11-02 1999-11-02 Threapeutic vaccines against variable viruses and other targets
CA002389339A CA2389339A1 (en) 1999-11-02 2000-11-01 Recombinant therapeutic fusion proteins
PCT/GB2000/004191 WO2001032893A1 (en) 1999-11-02 2000-11-01 Recombinant therapeutic fusion proteins
AT00973003T ATE358727T1 (de) 1999-11-02 2000-11-01 Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
HK03100373.4A HK1048335B (en) 1999-11-02 2000-11-01 Recombinant bifunctional fusion proteins for the clearance of variable viruses
EP00973003A EP1226256B1 (en) 1999-11-02 2000-11-01 Recombinant bifunctional fusion proteins for the clearance of variable viruses
JP2001535575A JP4768944B2 (ja) 1999-11-02 2000-11-01 組換え型の治療的融合タンパク
AU11560/01A AU1156001A (en) 1999-11-02 2000-11-01 Recombinant therapeutic fusion proteins
ES00973003T ES2284537T3 (es) 1999-11-02 2000-11-01 Proteinas de fusion bifuncionales recombinantes para la eliminacion de virus variables.
DE60034243T DE60034243T2 (de) 1999-11-02 2000-11-01 Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
US11/124,971 US7390881B2 (en) 1999-11-02 2005-05-09 Recombinant therapeutic fusion proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925966.5A GB9925966D0 (en) 1999-11-02 1999-11-02 Threapeutic vaccines against variable viruses and other targets

Publications (1)

Publication Number Publication Date
GB9925966D0 true GB9925966D0 (en) 1999-12-29

Family

ID=10863838

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9925966.5A Ceased GB9925966D0 (en) 1999-11-02 1999-11-02 Threapeutic vaccines against variable viruses and other targets

Country Status (11)

Country Link
US (1) US7390881B2 (cg-RX-API-DMAC7.html)
EP (1) EP1226256B1 (cg-RX-API-DMAC7.html)
JP (1) JP4768944B2 (cg-RX-API-DMAC7.html)
AT (1) ATE358727T1 (cg-RX-API-DMAC7.html)
AU (1) AU1156001A (cg-RX-API-DMAC7.html)
CA (1) CA2389339A1 (cg-RX-API-DMAC7.html)
DE (1) DE60034243T2 (cg-RX-API-DMAC7.html)
ES (1) ES2284537T3 (cg-RX-API-DMAC7.html)
GB (1) GB9925966D0 (cg-RX-API-DMAC7.html)
HK (1) HK1048335B (cg-RX-API-DMAC7.html)
WO (1) WO2001032893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
WO2006133497A1 (en) * 2005-06-15 2006-12-21 Adelaide Research & Innovation Pty Ltd Combination treatment
ES2337113B1 (es) * 2007-04-17 2011-01-24 Centre De Recerca En Sanitat Animal (Cresa) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante.
EP3947445A1 (en) 2019-04-04 2022-02-09 Vanderbilt University Hiv/hcv cross-reactive antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683211B2 (en) * 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
ATE288488T1 (de) * 1997-03-11 2005-02-15 Mayo Foundation Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
EP1085908B1 (en) 1998-06-11 2009-09-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein
ES2313886T3 (es) 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.

Also Published As

Publication number Publication date
WO2001032893A1 (en) 2001-05-10
ES2284537T3 (es) 2007-11-16
JP4768944B2 (ja) 2011-09-07
HK1048335A1 (en) 2003-03-28
HK1048335B (en) 2007-11-23
US7390881B2 (en) 2008-06-24
DE60034243T2 (de) 2007-12-20
US20050260220A1 (en) 2005-11-24
CA2389339A1 (en) 2001-05-10
EP1226256A1 (en) 2002-07-31
AU1156001A (en) 2001-05-14
ATE358727T1 (de) 2007-04-15
JP2003514518A (ja) 2003-04-22
EP1226256B1 (en) 2007-04-04
DE60034243D1 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
JP2013241442A5 (cg-RX-API-DMAC7.html)
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
EA199700215A1 (ru) Защита от вирусных инфекций путем колонизации слизистых оболочек генетически модифицированными бактериями
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
EA200100619A1 (ru) Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
ATE125821T1 (de) Vakzin gegen hepatitis b.
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
WO2002022686A3 (en) Defensin-antigen fusion proteins
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
SE9903031D0 (sv) Peptide mixture and vaccine against a chronic viral infection
AU1156001A (en) Recombinant therapeutic fusion proteins
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
DK373489D0 (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
WO1993017110A3 (en) A recombinant hepatitis c virus polypeptide
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
AU7546500A (en) Designing immunogens

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)